Unter metabolischen Nierenerkrankungen wird eine breite Gruppe von Erkrankungen zusammengefasst, die durch metabolische Störungen charakterisiert ist, welche letztendlich zu renalen Symptomen führen können.
1. |
Borsani G et al. (1999) SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. |
2. |
Purdue PE et al. (1990) Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. |
4. |
Mansfield E et al. (2001) The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. |
5. |
El-Shanti H et al. (2006) Familial mediterranean fever in Arabs. |
6. |
Bonyadi M et al. (2009) MEFV mutations in Iranian Azeri Turkish patients with familial Mediterranean fever. |
7. |
Yuval Y et al. (1995) Dominant inheritance in two families with familial Mediterranean fever (FMF). |
8. |
None (1997) A candidate gene for familial Mediterranean fever. |
9. |
None (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. |
10. |
Babior BM et al. (1997) The familial Mediterranean fever gene--cloned at last. |
11. |
Belostotsky R et al. (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. |
12. |
Cattan D et al. (2000) Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. |
13. |
Tamir N et al. (1999) Late-onset familial Mediterranean fever (FMF): a subset with distinct clinical, demographic, and molecular genetic characteristics. |
14. |
Brik R et al. (2001) Incidence of familial Mediterranean fever (FMF) mutations among children of Mediterranean extraction with functional abdominal pain. |
15. |
Milledge J et al. (2002) Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. |
16. |
None (2003) Should patients with FMF undergo BMT? |
17. |
Touitou I et al. (2003) Allogenic bone marrow transplantation: not a treatment yet for familial Mediterranean fever. |
18. |
Cazeneuve C et al. (2003) Familial Mediterranean fever among patients from Karabakh and the diagnostic value of MEFV gene analysis in all classically affected populations. |
19. |
HELLER H et al. (1961) Amyloidosis in familial Mediterranean fever. An independent genetically determined character. |
20. |
DORMER AE et al. (1962) Familial Mediterranean fever: a cause of periodic fever. |
21. |
None (1964) FAMILIAL PAROXYSMAL POLYSEROSITIS. ANALYSIS OF FIFTY CASES. |
22. |
Shohat M et al. (1992) Twin studies in familial Mediterranean fever. |
23. |
Shohat M et al. (1992) The gene for familial Mediterranean fever in both Armenians and non-Ashkenazi Jews is linked to the alpha-globin complex on 16p: evidence for locus homogeneity. |
24. |
Pras E et al. (1992) Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. |
25. |
Sack GH et al. (1991) Exclusion of linkage between familial Mediterranean fever and the human serum amyloid A (SAA) gene cluster. |
26. |
Touitou I et al. (2007) Transmission of familial Mediterranean fever mutations following bone marrow transplantation. |
27. |
Papadopoulos VP et al. (2008) The population genetics of familial mediterranean fever: a meta-analysis study. |
28. |
Shohat M et al. (1990) Serum amyloid A and P protein genes in familial Mediterranean fever. |
29. |
Shohat T et al. (1990) Familial Mediterranean fever--linkage studies with genetic markers on chromosome 6. |
30. |
Shohat T et al. (1990) Genetic marker family studies in familial Mediterranean fever (FMF) in Armenians. |
31. |
Lazarin GA et al. (2013) An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. |
32. |
Ayesh SK et al. (1990) Partial characterization of a C5a-inhibitor in peritoneal fluid. |
33. |
Shohat M et al. (1989) Hypothesis: familial Mediterranean fever--a genetic disorder of the lipocortin family? |
34. |
Majeed HA et al. (1989) Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. |
35. |
Rogers DB et al. (1989) Familial Mediterranean fever in Armenians: autosomal recessive inheritance with high gene frequency. |
36. |
None (1988) Serum amyloid A (SAA) gene variations in familial Mediterranean fever. |
37. |
Schwabe AD et al. (1988) Meningitis in familial Mediterranean fever. |
38. |
Benson MD et al. (1977) Amyloid deposition in a renal transplant in familial Mediterranean fever. |
39. |
Barakat MH et al. (1986) Familial Mediterranean fever (recurrent hereditary polyserositis) in Arabs--a study of 175 patients and review of the literature. |
40. |
Jones MB et al. (1977) Amyloidosis in a renal allograft in familial Mediterranean fever. |
41. |
Eshel G et al. (1988) Acute orchitis in familial Mediterranean fever. |
42. |
Barakat MH et al. (1988) Mollaret's meningitis. A variant of recurrent hereditary polyserositis, both provoked by metaraminol. |
43. |
Zemer D et al. (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. |
44. |
Schwabe AD et al. (1987) Recurrent polyserositis (familial Mediterranean fever) in a Japanese. |
45. |
Rubinger D et al. (1979) Amelioration of familial Mediterranean fever during hemodialysis. |
46. |
Knecht A et al. (1985) Serum amyloid A protein in familial Mediterranean fever. |
47. |
Schwabe AD et al. (1974) Familial Mediterranean Fever in Armenians. Analysis of 100 cases. |
48. |
Zemer D et al. (1974) A controlled trial of colchicine in preventing attacks of familial mediterranean fever. |
49. |
Dinarello CA et al. (1974) Colchicine therapy for familial mediterranean fever. A double-blind trial. |
50. |
None (1972) Colchicine for familial Mediterranean fever. |
51. |
Sohar E et al. (1967) Familial Mediterranean fever. A survey of 470 cases and review of the literature. |
52. |
Hurwich BJ et al. (1970) Record survival of siblings with familial Mediterranean fever, phenotypes 1 and 2. |
53. |
Reich CB et al. (1970) Familial Mediterranean fever in an Italian family. |
54. |
Ozdemir AI et al. (1969) Familial Mediterranean fever among the Turkish people. |
55. |
Barakat MH et al. (1984) Metaraminol provocative test: a specific diagnostic test for familial Mediterranean fever. |
56. |
Cattan D et al. (1984) Metaraminol provocation test for familial Mediterranean fever. |
57. |
Barakat MH et al. (1984) Diagnosing familial Mediterranean fever. |
58. |
Ilfeld D et al. (1982) Correction of a suppressor cell deficiency in four patients with familial Mediterranean fever by in vitro or in vivo colchicine. |
59. |
Matzner Y et al. (1984) Diminished activity of a chemotactic inhibitor in synovial fluids from patients with familial Mediterranean fever. |
60. |
Agmon D et al. () Isolated adrenal mineralocorticoid deficiency due to amyloidosis associated with familial Mediterranean fever. |
61. |
Schlesinger M et al. (1984) Familial Mediterranean fever: no linkage with HLA. |
62. |
Matzner Y et al. (1984) C5a-inhibitor deficiency in peritoneal fluids from patients with familial Mediterranean fever. |
63. |
Schwabe AD et al. (1984) C5a-inhibitor deficiency--a role in familial Mediterranean fever? |
64. |
None (1983) Enrollment bias and variation in clinical manifestations: a review of consecutive cases of familial paroxysmal polyserositis. |
65. |
Pras M et al. (1982) Variable incidence of amyloidosis in familial Mediterranean fever among different ethnic groups. |
66. |
Flatau E et al. (1982) Schönlein-Henoch syndrome in patients with familial Mediterranean fever. |
67. |
Ludomirsky A et al. (1981) Amyloidosis in children with familial Mediterranean fever. |
68. |
Daniels M et al. (1995) Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish populations in Israel. |
69. |
Pras E et al. (1994) The gene causing familial Mediterranean fever maps to the short arm of chromosome 16 in Druze and Moslem Arab families. |
70. |
Ozyilkan E et al. (1994) Absence of asthma in patients with familial Mediterranean fever. |
71. |
Aksentijevich I et al. (1993) Refined mapping of the gene causing familial Mediterranean fever, by linkage and homozygosity studies. |
72. |
Aksentijevich I et al. (1993) Evidence for linkage of the gene causing familial Mediterranean fever to chromosome 17q in non-Ashkenazi Jewish families: second locus or type I error? |
73. |
Fischel-Ghodsian N et al. (1993) Regional mapping of the gene for familial Mediterranean fever on human chromosome 16p13. |
74. |
Zemer D et al. (1993) Familial Mediterranean fever in the colchicine era: the fate of one family. |
75. |
Levy EN et al. (1996) Linkage disequilibrium mapping places the gene causing familial Mediterranean fever close to D16S246. |
76. |
Ben-Chetrit E et al. (1996) Colchicine in breast milk of patients with familial Mediterranean fever. |
77. |
None (1996) Localization of the familial Mediterranean fever gene (FMF) to a 250-kb interval in non-Ashkenazi Jewish founder haplotypes. The French FMF Consortium. |
78. |
None (1977) Familial Mediterranean fever. Recent advances in pathogenesis and management. |
79. |
Rawashdeh MO et al. (1996) Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. |
80. |
Dupont M et al. (1997) Genotypic diagnosis of familial Mediterranean fever (FMF) using new microsatellite markers: example of two extensive non-Ashkenazi Jewish pedigrees. |
81. |
Sood R et al. (1997) Construction of a 1-Mb restriction-mapped cosmid contig containing the candidate region for the familial Mediterranean fever locus (MEFV) on chromosome 16p 13.3. |
82. |
Ravid M et al. (1977) Prolonged colchicine treatment in four patients with amyloidosis. |
83. |
Akarsu AN et al. (1997) Genetic linkage study of familial Mediterranean fever (FMF) to 16p13.3 and evidence for genetic heterogeneity in the Turkish population. |
84. |
Saatçi U et al. (1997) Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. |
85. |
Pras E et al. (1998) Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. |
86. |
Yazigi A et al. (1998) Colchicine for recurrent pericarditis in children. |
87. |
Germain DP et al. (1999) Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. |
88. |
Ohshima T et al. (1999) Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. |
89. |
Schiffmann R et al. (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. |
90. |
Takenaka T et al. (2000) Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. |
91. |
Asano N et al. (2000) In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. |
92. |
Brady RO et al. (2000) Clinical features of and recent advances in therapy for Fabry disease. |
93. |
Ioannou YA et al. (2001) Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. |
94. |
Prigozy TI et al. (2001) Glycolipid antigen processing for presentation by CD1d molecules. |
95. |
Eng CM et al. (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. |
96. |
Jung SC et al. (2001) Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. |
97. |
Qin G et al. (2001) Preselective gene therapy for Fabry disease. |
98. |
Schiffmann R et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. |
99. |
Pastores GM et al. (2001) Enzyme-replacement therapy for Anderson-Fabry disease. |
100. |
None (2001) Co-occurrence and contribution of Fabry disease and Klippel-Trénaunay-Weber syndrome to a patient with atypical skin lesions. |
101. |
MacDermot KD et al. (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. |
102. |
MacDermot KD et al. (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. |
103. |
Whybra C et al. (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. |
104. |
Branton MH et al. (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. |
105. |
Romeo G et al. (1972) Genetic heterogeneity of alpha-galactosidase in fabry's disease. |
106. |
Heltianu C et al. (2002) Endothelial nitric oxide synthase gene polymorphisms in Fabry's disease. |
107. |
Takahashi H et al. (2002) Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. |
109. |
Blom D et al. (2003) Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. |
110. |
Senechal M et al. (2003) Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. |
111. |
None (2003) PR interval and the response to enzyme-replacement therapy for Fabry's disease. |
112. |
Nakao S et al. (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. |
113. |
WISE D et al. (1962) Angiokeratoma corporis diffusum. A clinical study of eight affected families. |
114. |
SWEELEY CC et al. (1963) FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID. |
115. |
HAMBURGER J et al. (1964) [ON AN UNUSUAL FAMILIAL MALFORMATION OF THE RENAL EPITHELIUM]. |
116. |
RAHMAN AN et al. (1961) Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis). |
117. |
Wilcox WR et al. (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. |
118. |
Verovnik F et al. (2004) Remarkable variability in renal disease in a large Slovenian family with Fabry disease. |
119. |
Spinelli L et al. (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. |
120. |
Germain DP et al. (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. |
121. |
Rolfs A et al. (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. |
122. |
Prüss H et al. (2006) Paroxysmal vertigo as the presenting symptom of Fabry disease. |
123. |
Nagao Y et al. (1991) Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. |
124. |
Nance CS et al. (2006) Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. |
125. |
Mastropasqua L et al. (2006) Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study. |
126. |
Spada M et al. (2006) High incidence of later-onset fabry disease revealed by newborn screening. |
128. |
Faggiano A et al. (2006) Endocrine dysfunction in patients with Fabry disease. |
129. |
Eng CM et al. (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. |
130. |
Kaneski CR et al. (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. |
131. |
Wang RY et al. (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. |
132. |
Kim W et al. (2007) Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy. |
133. |
Moore DF et al. (2007) The cerebral vasculopathy of Fabry disease. |
134. |
None (2007) Narrative review: Fabry disease. |
135. |
Opitz JM et al. (1965) The Genetics of Angiokeratoma Corporis Diffusum (Fabry's Disease) and Its Linkage Relations with the Xg Locus. |
136. |
Auray-Blais C et al. (2008) Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. |
137. |
Aerts JM et al. (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. |
138. |
von Scheidt W et al. (1991) An atypical variant of Fabry's disease with manifestations confined to the myocardium. |
139. |
Fellgiebel A et al. (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. |
140. |
Mehta A et al. (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. |
141. |
Waldek S et al. (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. |
142. |
Tajima Y et al. (2009) Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. |
143. |
Crosbie TW et al. (2009) Psychological aspects of patients with Fabry disease. |
144. |
Testai FD et al. (2010) Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. |
145. |
None () [Not Available]. |
146. |
None (1946) [Not Available]. |
147. |
Beaudet AL et al. (1978) Detection of Fabry's disease heterozygotes by hair root analysis. |
148. |
Ogawa K et al. (1990) Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. |
149. |
Kornreich R et al. (1990) Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene. |
150. |
Hasholt L et al. (1990) A Fabry's disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. |
151. |
Bird TD et al. (1978) Neurological manifestations of Fabry disease in female carriers. |
152. |
Elleder M et al. (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. |
153. |
Spence MW et al. (1978) Angiokeratoma corporis diffusum (Anderson-Fabry disease) in a single large family in Nova Scotia. |
154. |
Hamers MN et al. (1979) Relationship between biochemical and clinical features in an English Anderson-Fabry family. |
155. |
Bernstein HS et al. (1989) Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. |
156. |
MacDermot KD et al. (1987) Anderson Fabry disease, a close linkage with highly polymorphic DNA markers DXS17, DXS87 and DXS88. |
157. |
Rodriguez FH et al. (1985) Fabry's disease in a heterozygous woman. |
158. |
Hasholt L et al. (1986) Lysosomal alpha-galactosidase in endothelial cell cultures established from a Fabry hemizygous and normal umbilical veins. |
159. |
Lemansky P et al. (1987) Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. |
160. |
Efthimiou J et al. (1986) Short PR intervals and tachyarrhythmias in Fabry's disease. |
161. |
Sakuraba H et al. (1986) Cardiovascular manifestations in Fabry's disease. A high incidence of mitral valve prolapse in hemizygotes and heterozygotes. |
162. |
Friedlaender MM et al. (1987) Renal biopsy in Fabry's disease eight years after successful renal transplantation. |
163. |
Mutoh T et al. (1988) Severe orthostatic hypotension in a female carrier of Fabry's disease. |
164. |
Ropers HH et al. (1977) Evidence for preferential X-chromosome inactivation in a family with Fabry disease. |
165. |
Peltier A et al. (1977) Pseudo-clinical Fabry's disease without alpha galactosidase deficiency. |
166. |
Loonen MC et al. (1974) Letter: Angiokeratoma corporis diffusum and lysosomal enzyme deficiency. |
167. |
Roudebush CP et al. (1973) The abbreviated PR interval of Fabry's disease. |
168. |
Mapes CA et al. (1970) Enzyme replacement in Fabry's disease, an inborn error of metabolism. |
169. |
Flynn DM et al. (1972) Gut lesions in Fabry's disease without a rash. |
170. |
Patel V et al. (1972) Deficiency of alpha-L-fucosidase. |
171. |
Johnston AW et al. (1969) Linkage relationships of the angiokeratoma (Fabry) locus. |
172. |
None (1970) Fabry's disease: alpha-galactosidase deficiency. |
173. |
Romeo G et al. (1970) Genetic inactivation of the alpha-galactosidase locus in carriers of Fabry's disease. |
174. |
Clarke JT et al. (1971) Ceramide trihexosidosis (fabry's disease) without skin lesions. |
175. |
Philippart M et al. (1969) Urinary glycolipids in Fabry's disease. Their examination in the detection of atypical variants and the pre-symptomatic state. |
176. |
Franceschetti AT et al. (1969) A study of Fabry's disease. I. Clinical examination of a family with cornea verticillata. |
177. |
Frost P et al. (1966) Fabry's disease--glycolipid lipidosis. Histochemical and electron microscopic studies of two cases. |
178. |
Brady RO et al. (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. |
179. |
Rosenberg DM et al. (1980) Chronic airflow obstruction in Fabry's disease. |
180. |
Broadbent JC et al. (1981) Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy. |
181. |
Sheth KJ et al. (1981) Heterozygote detection in Fabry disease utilizing multiple enzyme activities. |
182. |
Johnston AW et al. (1981) Linkage relationship of the loci for Anderson--Fabry disease and the Xg blood groups. |
183. |
Cable WJ et al. (1982) Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. |
184. |
Tagliavini F et al. (1982) Anderson-Fabry's disease: neuropathological and neurochemical investigation. |
185. |
Bach G et al. (1982) Pseudodeficiency of alpha-galactosidase A. |
186. |
Clement M et al. (1982) Renal transplantation in Anderson-Fabry disease. |
187. |
Cable WJ et al. (1982) Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment. |
188. |
None (1982) [Fabry's disease. Light and electron microscopic cardiac findings 12 years after successful kidney transplantation]. |
189. |
Friedman LS et al. (1984) Jejunal diverticulosis with perforation as a complication of Fabry's disease. |
190. |
Maisey DN et al. (1980) Basilar artery aneurysm and Anderson-Fabry disease. |
191. |
Sørensen SA et al. (1980) alpha-Galactosidase isozymes in normal individuals, and in Fabry hemizygotes and heterozygotes. |
192. |
Pyeritz RE et al. (1980) Plasma exchange removes glycosphingolipid in Fabry disease. |
193. |
Faraggiana T et al. (1981) Light- and electron-microscopic histochemistry of Fabry's disease. |
194. |
Cable WJ et al. (1982) Fabry disease: impaired autonomic function. |
195. |
Colucci WS et al. (1982) Hypertrophic obstructive cardiomyopathy due to Fabry's disease. |
196. |
Novo FJ et al. (1995) Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion. |
197. |
Eng CM et al. (1993) Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. |
198. |
Nakao S et al. (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. |
199. |
Hillsley RE et al. (1995) Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease. |
200. |
Elleder M et al. (1994) Leptomeningeal lipid storage patterns in Fabry disease. |
201. |
Eng CM et al. (1994) Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. |
202. |
Halsted CH et al. (1975) Letter: Occurrence of celiac sprue in a patient with Fabry's disease. |
203. |
Spence MW et al. (1976) Failure to correct the metabolic defect by renal allotransplantion in Fabry's disease. |
204. |
Pierides AM et al. (1976) Study on a family with anderson--Fabry's disease and associated familial spastic paraplegia. |
205. |
Davies JP et al. (1993) Mutation analysis in patients with the typical form of Anderson-Fabry disease. |
206. |
Ko YH et al. (1996) Atypical Fabry's disease. An oligosymptomatic variant. |
207. |
Ishii S et al. (1996) Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum. |
208. |
Sawada K et al. (1996) Point mutation in the alpha-galactosidase A gene of atypical Fabry disease with only nephropathy. |
209. |
Blanch LC et al. (1996) A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. |
210. |
Germain D et al. (1996) Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the alpha-galactosidase A gene and detection of carriers in Fabry disease. |
211. |
Brown LK et al. (1997) Pulmonary involvement in Fabry disease. |
212. |
Ohshima T et al. (1997) alpha-Galactosidase A deficient mice: a model of Fabry disease. |
213. |
Fan JQ et al. (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. |
214. |
Norio R et al. (1971) Lysinuric protein intolerance, an autosomal recessive disease. A genetic study of 10 Finnish families. |
215. |
Torrents D et al. (1999) Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. |
216. |
Sperandeo MP et al. (1999) Feasibility of prenatal diagnosis of lysinuric protein intolerance by linkage analysis: a case report. |
217. |
Pirulli D et al. (1999) Molecular analysis of hyperoxaluria type 1 in Italian patients reveals eight new mutations in the alanine: glyoxylate aminotransferase gene. |
218. |
Cramer SD et al. (1999) The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. |
219. |
Walden U et al. (1999) Primary hyperoxaluria 1: catch up growth and normalization of oxaluria 6 years after hepatorenal transplantation in a prepubertal boy. |
220. |
Cochat P et al. (1999) Primary hyperoxaluria in infants: medical, ethical, and economic issues. |
221. |
Mykkänen J et al. (2000) Functional analysis of novel mutations in y(+)LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI). |
222. |
Noguchi A et al. (2000) SLC7A7 genomic structure and novel variants in three Japanese lysinuric protein intolerance families. |
223. |
Simell O et al. (1975) Lysinuric protein intolerance. |
224. |
Theodossiadis PG et al. (2002) Choroidal neovascularization in primary hyperoxaluria. |
225. |
FREDERICK EW et al. (1963) STUDIES ON PRIMARY HYPEROXALURIA. I. IN VIVO DEMONSTRATION OF A DEFECT IN GLYOXYLATE METABOLISM. |
226. |
Sperandeo MP et al. (2008) Lysinuric protein intolerance: update and extended mutation analysis of the SLC7A7 gene. |
227. |
Font-Llitjós M et al. (2009) Novel SLC7A7 large rearrangements in lysinuric protein intolerance patients involving the same AluY repeat. |
228. |
Williams EL et al. (2009) Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. |
230. |
Nishiyama K et al. (1991) Primary hyperoxaluria type I due to a point mutation of T to C in the coding region of the serine:pyruvate aminotransferase gene. |
231. |
Seargeant LE et al. (1991) Primary oxaluria type 2 (L-glyceric aciduria): a rare cause of nephrolithiasis in children. |
232. |
Wang RY et al. (2011) Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. |
233. |
Latta K et al. (1990) Primary hyperoxaluria type I. |
234. |
Small KW et al. (1990) Ocular findings in primary hyperoxaluria. |
235. |
Takada Y et al. (1990) Human peroxisomal L-alanine: glyoxylate aminotransferase. Evolutionary loss of a mitochondrial targeting signal by point mutation of the initiation codon. |
236. |
Van Schaftingen E et al. (1989) Coenzyme specificity of mammalian liver D-glycerate dehydrogenase. |
237. |
Shaw PJ et al. (1989) Familial lysinuric protein intolerance presenting as coma in two adult siblings. |
238. |
McDonald JC et al. (1989) Reversal by liver transplantation of the complications of primary hyperoxaluria as well as the metabolic defect. |
239. |
Danpure CJ et al. (1987) Enzymological diagnosis of primary hyperoxaluria type 1 by measurement of hepatic alanine: glyoxylate aminotransferase activity. |
240. |
Danpure CJ et al. (1988) Prenatal exclusion of primary hyperoxaluria type 1. |
241. |
Danpure CJ et al. (1989) An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. |
243. |
Smith DW et al. (1988) Lysinuric protein intolerance mutation is not expressed in the plasma membrane of erythrocytes. |
244. |
Danpure CJ et al. (1988) Further studies on the activity and subcellular distribution of alanine:glyoxylate aminotransferase in the livers of patients with primary hyperoxaluria type 1. |
245. |
Baethge BA et al. (1988) Livedo reticularis and peripheral gangrene associated with primary hyperoxaluria. |
246. |
Danpure CJ et al. (1986) Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. |
247. |
Watts RW et al. (1985) Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation. |
248. |
Carpenter TO et al. (1985) Lysinuric protein intolerance presenting as childhood osteoporosis. Clinical and skeletal response to citrulline therapy. |
249. |
Yendt ER et al. (1985) Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. |
250. |
Kihara H et al. (1973) Hyperdibasicaminoaciduria in a mentally retarded homozygote with a peculiar response to phenothiazines. |
251. |
Perheentupa J et al. (1965) Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism. |
252. |
Williams HE et al. (1971) Hyperoxaluria in L-glyceric aciduria: possible pathogenic mechanism. |
253. |
Will EJ et al. (1979) Primary oxalosis: clinical and biochemical response to high-dose pyridoxine therapy. |
254. |
Boquist L et al. (1973) Primary oxalosis. |
255. |
Klauwers J et al. (1969) Failure of renal transplantation in primary oxalosis. |
256. |
Bourke E et al. (1972) Primary hyperoxaluria with normal alpha-ketoglutarate: glyoxylate carboligase activity. Treatment with isocarboxazid. |
257. |
Koch J et al. (1967) Deficiency of 2-oxo-glutarate: glyoxylate carboligase activity in primary hyperoxaluria. |
258. |
Oyanagi K et al. (1970) Congenital lysinuria: a new inherited transport disorder of dibasic amino acids. |
259. |
Dent CE et al. (1970) Treatment of primary hyperoxaluria. |
260. |
None (1970) [Heredity of familial oxalosis]. |
261. |
Malmquist J et al. (1971) Familial protein intolerance. Possible nature of enzyme defect. |
262. |
Coltart DJ et al. (1971) Primary oxalosis of the heart: a cause of heart block. |
263. |
Williams HE et al. (1968) L-glyceric aciduria. A new genetic variant of primary hyperoxaluria. |
264. |
Kekomäki M et al. (1968) Familial protein intolerance with deficient transport of basic amino acids. Report on an adult patient with chronic hyperammonemia. |
265. |
Hockaday TD et al. (1965) The metabolic error in primary hyperoxaluria. |
266. |
Kekomäki M et al. (1967) Familial protein intolerance with deficient transport of basic amino acids. An analysis of 10 patients. |
267. |
Massie BM et al. (1981) Primary oxalosis with pan-conduction cardiac disease: electrophysiologic and anatomic correlation. |
268. |
Berger A et al. (1984) More on neuropathy from pyridoxine abuse. |
269. |
Dennis AJ et al. (1980) Nitroglycerin as a remedy for peripheral vascular insufficiency associated with oxalosis. |
270. |
Rajantie J et al. (1980) Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine. |
271. |
Kato T et al. (1982) Renal transport of lysine and arginine in lysinuric protein intolerance. |
272. |
Chesney RW et al. (1983) Renal failure with hypercalcemia, renal stones, multiple pathologic fractures, and growth failure. |
273. |
O'Regan PF et al. (1980) Primary hyperoxaluria. |
274. |
Morris MC et al. (1982) Oxalosis in infancy. |
275. |
Rajantie J et al. (1981) Lysinuric protein intolerance. Basolateral transport defect in renal tubuli. |
276. |
Milliner DS et al. (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. |
277. |
Parto K et al. (1994) Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. |
278. |
None (1993) Primary hyperoxaluria type 1 and peroxisome-to-mitochondrion mistargeting of alanine:glyoxylate aminotransferase. |
279. |
McManus DT et al. (1996) Necropsy findings in lysinuric protein intolerance. |
280. |
Danpure CJ et al. (1996) Strategies for the prenatal diagnosis of primary hyperoxaluria type 1. |
281. |
Parsons H et al. (1996) Immune complex disease consistent with systemic lupus erythematosus in a patient with lysinuric protein intolerance. |
282. |
Lauteala T et al. (1997) Lysinuric protein intolerance (LPI) gene maps to the long arm of chromosome 14. |
283. |
Kemper MJ et al. (1997) Primary hyperoxaluria type 2. |
284. |
None (1998) Preemptive liver transplantation from a living related donor for primary hyperoxaluria type I. |
285. |
Lauteala T et al. () Genetic homogeneity of lysinuric protein intolerance. |
286. |
Duval M et al. (1999) Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance. |